Skip to main content
. 2019 Jan 9;17:8. doi: 10.1186/s12916-018-1233-1

Fig. 5.

Fig. 5

Rates of pathological complete response (pCR) according to the type of chemotherapy and anti-HER2 therapy using data from 15 neoadjuvant clinical trials in HER2-positive breast cancer. Bars denote 95% CIs. T taxane, L lapatinib, H herceptin (trastuzumab), A/T anthracycline/taxane based